A detailed history of Kbc Group Nv transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Kbc Group Nv holds 2,339 shares of SRPT stock, worth $285,124. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,339
Previous 2,101 11.33%
Holding current value
$285,124
Previous $332,000 12.05%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$124.33 - $156.75 $29,590 - $37,306
238 Added 11.33%
2,339 $292,000
Q2 2024

Jul 17, 2024

BUY
$113.33 - $163.85 $19,606 - $28,346
173 Added 8.97%
2,101 $332,000
Q1 2024

May 08, 2024

BUY
$93.7 - $141.53 $41,977 - $63,405
448 Added 30.27%
1,928 $250,000
Q4 2023

Feb 13, 2024

BUY
$67.31 - $124.76 $99,618 - $184,644
1,480 New
1,480 $143,000
Q4 2021

Feb 03, 2022

SELL
$77.28 - $99.42 $42,890 - $55,178
-555 Closed
0 $0
Q3 2021

Nov 10, 2021

SELL
$65.97 - $92.48 $418,711 - $586,970
-6,347 Reduced 91.96%
555 $51,000
Q2 2021

Aug 11, 2021

SELL
$69.38 - $86.75 $2,567 - $3,209
-37 Reduced 0.53%
6,902 $536,000
Q3 2020

Oct 28, 2020

SELL
$127.12 - $172.34 $393,563 - $533,564
-3,096 Reduced 30.85%
6,939 $975,000
Q2 2020

Aug 10, 2020

BUY
$93.0 - $171.7 $190,650 - $351,985
2,050 Added 25.67%
10,035 $1.61 Million
Q1 2020

May 04, 2020

BUY
$82.38 - $131.64 $209,574 - $334,892
2,544 Added 46.76%
7,985 $781,000
Q4 2019

Feb 11, 2020

BUY
$76.53 - $135.58 $255,686 - $452,972
3,341 Added 159.1%
5,441 $702,000
Q3 2019

Nov 07, 2019

BUY
$72.81 - $156.91 $108,122 - $233,011
1,485 Added 241.46%
2,100 $158,000
Q2 2019

Dec 03, 2019

BUY
$112.21 - $151.95 $69,009 - $93,449
615 New
615 $93,000
Q2 2019

Jul 30, 2019

SELL
$112.21 - $151.95 $69,009 - $93,449
-615 Closed
0 $0
Q1 2019

Dec 03, 2019

BUY
$106.67 - $151.68 $65,602 - $93,283
615 New
615 $73,000

Others Institutions Holding SRPT

About Sarepta Therapeutics, Inc.


  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $10.7B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track This Portfolio

Track Kbc Group Nv Portfolio

Follow Kbc Group Nv and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

News

Stay updated on Kbc Group Nv with notifications on news.